Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

1.7K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
1.7K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

73.1K
Overview
73.1K
T Cell Types and Functions01:24

T Cell Types and Functions

1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

6.1K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
6.1K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

4.3K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Whole-genome doubling drives immune evasion by silencing antigen presentation.

Cancer cell·2026
Same author

Targeting the p53 pathway to treat atypical teratoid rhabdoid tumors.

Neuro-oncology pediatrics·2026
Same author

A glucocorticoid-FAS axis controls immune evasion during metastatic seeding.

Nature·2026
Same author

Stress-induced sympathetic hyperactivation drives hair follicle necrosis to trigger autoimmunity.

Cell·2025
Same author

Nisin, a promising antimicrobial peptide, forestalls the methicillin-resistant <i>Staphylococcus aureus</i> biofilm network via reactive oxygen species generation.

3 Biotech·2025
Same author

Decoding the spatial dynamics of tumor and immune cell interactions in solid cancers.

Cancer cell·2025
Same journal

Itaconate in cancer immunity: Evidence, ambiguities, and translational barriers.

Trends in cancer·2026
Same journal

Patient-derived organoids in hematologic malignancies: Fidelity and translation beyond animals.

Trends in cancer·2026
Same journal

Precision neuro-oncology for children: Time to gear up!

Trends in cancer·2026
Same journal

Multi-omics analysis of extracellular vesicle cargo in cancer.

Trends in cancer·2026
Same journal

An immunological panacea for cancer-related cachexia.

Trends in cancer·2026
Same journal

Beyond one gene, one target: Next-generation precision oncology.

Trends in cancer·2026
See all related articles

Related Experiment Video

Updated: Sep 14, 2025

Bone Conditioned Medium: Preparation and Bioassay
07:18

Bone Conditioned Medium: Preparation and Bioassay

Published on: July 8, 2015

11.2K

Bone appetite: bone-derived factors feed distant immune suppression.

Debolina Ganguly1, Judith Agudo2

  • 1Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02215, USA; Parker Institute for Cancer Immunotherapy at Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Trends in Cancer
|July 18, 2025
PubMed
Summary
This summary is machine-generated.

Bone metastases impair the immune system, hindering immunotherapy effectiveness. Osteopontin produced by bone tumors suppresses immunity in distant sites, revealing a new mechanism of cancer immune evasion.

Keywords:
immunotherapyorgan crosstalksystemic factors

More Related Videos

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.4K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.5K

Related Experiment Videos

Last Updated: Sep 14, 2025

Bone Conditioned Medium: Preparation and Bioassay
07:18

Bone Conditioned Medium: Preparation and Bioassay

Published on: July 8, 2015

11.2K
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.4K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.5K

Area of Science:

  • Oncology
  • Immunology
  • Cancer Metastasis

Background:

  • The location of metastatic cancer significantly impacts treatment outcomes.
  • Understanding systemic effects of metastases is crucial for effective cancer therapy.

Purpose of the Study:

  • To investigate how bone metastases affect systemic immune function.
  • To identify mechanisms by which bone metastases hinder immunotherapy response.

Main Methods:

  • Analysis of a study by Cheng et al. in Cancer Cell.
  • Examination of immune function in the context of bone metastases.

Main Results:

  • Bone metastases were found to cause a systemic decline in immune function.
  • Osteopontin (OPN) production by bone metastases was identified as a key factor suppressing immunity in distant lesions.
  • This indicates a novel cross-organ communication pathway that compromises anti-tumor immunity.

Conclusions:

  • Bone metastases create an immunosuppressive environment that limits immunotherapy efficacy.
  • Targeting osteopontin or related pathways may restore immune function and improve cancer treatment outcomes.